The effective and safe administration of Epcoritamab in relapsed CD19-CD5+ DLBCL following CAR-T therapy.

Shimakawa T, Kawano N, Semba Y, Mori Y, Takigawa K, Yamauchi T, Miyawaki K, Jinnouchi F, Sakoda T, Mori K, Shimo M, Otsu M, Ikeda R, Shiraishi S, Nakaike T, Yamashita K, Mashiba K, Kikuchi I, Marutsuka K, Ohshima K, Matsuzaki S, Karube K, Kato K, Maeda T, Akashi K

Open source

DOI: 10.31547/bct-2024-037
Published: 2025 Aug 25
Container: Blood cell therapy
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.31547/bct-2024-037,
  title = {The effective and safe administration of Epcoritamab in relapsed CD19-CD5+ DLBCL following CAR-T therapy.},
  author = {Shimakawa T and Kawano N and Semba Y and Mori Y and Takigawa K and Yamauchi T and Miyawaki K and Jinnouchi F and Sakoda T and Mori K and Shimo M and Otsu M and Ikeda R and Shiraishi S and Nakaike T and Yamashita K and Mashiba K and Kikuchi I and Marutsuka K and Ohshima K and Matsuzaki S and Karube K and Kato K and Maeda T and Akashi K},
  year = {2025},
  journal = {Blood cell therapy},
  doi = {10.31547/bct-2024-037},
  url = {https://doi.org/10.31547/bct-2024-037}
}

RIS

TY  - JOUR
TI  - The effective and safe administration of Epcoritamab in relapsed CD19-CD5+ DLBCL following CAR-T therapy.
AU  - Shimakawa T
AU  - Kawano N
AU  - Semba Y
AU  - Mori Y
AU  - Takigawa K
AU  - Yamauchi T
AU  - Miyawaki K
AU  - Jinnouchi F
AU  - Sakoda T
AU  - Mori K
AU  - Shimo M
AU  - Otsu M
AU  - Ikeda R
AU  - Shiraishi S
AU  - Nakaike T
AU  - Yamashita K
AU  - Mashiba K
AU  - Kikuchi I
AU  - Marutsuka K
AU  - Ohshima K
AU  - Matsuzaki S
AU  - Karube K
AU  - Kato K
AU  - Maeda T
AU  - Akashi K
PY  - 2025
JO  - Blood cell therapy
DO  - 10.31547/bct-2024-037
UR  - https://doi.org/10.31547/bct-2024-037
ER  -

APA

T, S., N, K., Y, S., Y, M., K, T., T, Y., K, M., F, J., T, S., K, M., M, S., M, O., R, I., S, S., T, N., K, Y., K, M., I, K., K, M., K, O., S, M., K, K., K, K., T, M., & K, A. (2025). The effective and safe administration of Epcoritamab in relapsed CD19-CD5+ DLBCL following CAR-T therapy.. Blood cell therapy. https://doi.org/10.31547/bct-2024-037

Source records

pubmed · retrieved 2026-09-27T12:46:09.995Z